Exodus Point Capital Management, LP Eli Lilly & CO Call Options Transaction History

Exodus Point Capital Management, LP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$772.14 - $960.02 $2.93 Million - $3.65 Million	-3,800 Reduced 90.48%	400 $354,000
Q2 2024 Aug 13, 2024	SELL	$724.87 - $909.04 $4.06 Million - $5.09 Million	-5,600 Reduced 57.14%	4,200 $3.81 Million
Q1 2024 May 14, 2024	BUY	$592.2 - $792.28 $5.8 Million - $7.76 Million	9,800 New	9,800 $7.61 Million

4,003

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $709B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.